Γ

SynBioBeta Speaker

Christopher Vakulskas

Integrated DNA Technologies

Sr. Dir. of Enzyme Dev.

Christopher Vakulskas, PhD is Senior Director of Enzyme Development at Integrated DNA Technologies (IDT), where he leads teams building next‑generation enzymes and molecular biology platforms spanning genome editing, diagnostics, and synthetic biology. Since joining IDT in 2015, his work has focused on translating protein engineering advances into robust, scalable products used across research, clinical, and industrial settings.Chris has led the development of widely adopted CRISPR nuclease technologies, including HiFi/SpyFi Cas9 and Cas12a Ultra, enabling improved specificity and performance in genome editing applications. He has also advanced innovations in qPCR and diagnostics, including extraction‑free molecular detection workflows for viral testing.At the core of Chris’s work is enabling faster build–test–learn cycles—where complex sequence designs become real, testable biology. He brings a practical perspective on the constraints that matter in synthetic biology at scale: how DNA complexity, accuracy, turnaround time, and downstream measurement (often by NGS) shape what is possible to design, build, and iterate. His teams and collaborators have helped push the limits of complex DNA design and manufacturability, supporting new synthetic biology products and applications.Chris earned a BS in Genetics and Biotechnology and a PhD in Microbiology (University of Iowa), completed postdoctoral training at the National Institutes of Health, and was recognized as a Distinguished Alumnus by the University of Florida.

Sessions Featuring

Christopher

This Year

Breakout Session

3:30 PM

-

4:15 PM

Tools & Tech

Breaking the Barriers of DNA Synthesis: Shattering the Ceiling?

For decades, DNA synthesis has been the limiting reagent in synthetic biology — reliable for short sequences, but increasingly error-prone and costly as designs scale. That ceiling is now cracking. New enzymatic synthesis platforms, error-correction chemistries, and assembly pipelines are extending what’s possible, opening the door to rapid construction of full pathways, microbial genomes, and even mammalian chromosomes. This session will explore how innovators are breaking past barriers, what technical and economic breakthroughs are needed next, and how longer, cheaper, and faster synthesis could fundamentally change how we design biology at scale.

Breakout Session

3:30 PM

-

4:15 PM

Tools & Tech

Breaking the Barriers of DNA Synthesis: Shattering the Ceiling?

For decades, DNA synthesis has been the limiting reagent in synthetic biology — reliable for short sequences, but increasingly error-prone and costly as designs scale. That ceiling is now cracking. New enzymatic synthesis platforms, error-correction chemistries, and assembly pipelines are extending what’s possible, opening the door to rapid construction of full pathways, microbial genomes, and even mammalian chromosomes. This session will explore how innovators are breaking past barriers, what technical and economic breakthroughs are needed next, and how longer, cheaper, and faster synthesis could fundamentally change how we design biology at scale.

Breakout Session

3:30 PM

-

4:15 PM

Human Health

Skip the Assembly, Go Straight to Your Next Breakthrough: How Innovative DNA Synthesis Is Changing What's Possible in Biopharma

The synthetic DNA field has entered an era of rapid innovation that is giving biopharma scientists new options when deciding whether to build or buy long and complex DNA. Previously hard-to-source DNA constructs are now readily available with an unprecedented guarantee for on-time shipping, eliminating procurement delays and empowering researchers to push the boundaries of synthetic biology. In this session, leading scientists will discuss how these advances are expanding design possibilities, accelerating design–build–test–learn cycles, and paving the way for the next wave of precision biotherapeutics.

Breakout Session

3:30 PM

-

4:15 PM

Human Health

Skip the Assembly, Go Straight to Your Next Breakthrough: How Innovative DNA Synthesis Is Changing What's Possible in Biopharma

The synthetic DNA field has entered an era of rapid innovation that is giving biopharma scientists new options when deciding whether to build or buy long and complex DNA. Previously hard-to-source DNA constructs are now readily available with an unprecedented guarantee for on-time shipping, eliminating procurement delays and empowering researchers to push the boundaries of synthetic biology. In this session, leading scientists will discuss how these advances are expanding design possibilities, accelerating design–build–test–learn cycles, and paving the way for the next wave of precision biotherapeutics.

TBD

Session lineup still growing

Featuring

Speaker Coming Soon

Fireside Chat

12:00 AM

-

8:30 AM

Human Health

From Cells to Patients: Solving the Scale Mismatch in Virtual Biology

Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?

Featuring

Speaker Coming Soon

Previous Speakers Include